Treatment

REGN5093 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER
This study is testing a new medicine, REGN5093, for people with a type of advanced lung cancer called non-small cell lung cancer, which has a specific change in their genes (MET-altered). It's looking to see if the medicine is safe and how well it works.
For: MET-altered non-small cell lung cancer (NSCLC)
France